Epithalon Where to Buy: The Paperwork Replaces the Label

Epithalon where to buy is a paperwork question before it is a shopping question, and the reason is worth sitting with for a moment. A prescription medicine hands you a great deal for free. An approved label states the strength, an inspected manufacturer stands behind the sterility, a pharmacist checks the dispensing, and if any of it turns out to be wrong there is a named party who is accountable for it. Epithalon has none of that anywhere in the West. What sits in that space instead is a certificate of analysis tied to a batch number, and reading one properly is the whole of the skill this page is trying to hand over.

Get the compound right first, because a surprising share of listings do not. Epithalon is a synthetic tetrapeptide: four residues, in the order Ala-Glu-Asp-Gly, catalogued at PubChem CID 219042 with the formula C14H22N4O9 and a molecular weight of 390.35. It came out of Russian work by Khavinson and colleagues on a pineal extract called epithalamin. FDA and PubChem spell it Epitalon; the market that sells it spells it Epithalon, so a search for epitalon where to buy lands on exactly the same shelf. They are one molecule with two spellings. What they are not is any of the peptides sold beside them, and the confusion is constant: a page calling this a heptapeptide has mixed it up with Selank or Semax, and one describing a fifteen-residue chain is talking about BPC-157.

One supplier is linked on this page and we earn a commission if you buy through it, which our affiliate disclosure sets out in full. That is precisely why the criteria below are written down before any supplier is scored against them, and why the section after the score is about what the certificate cannot tell you.

Most buying guides on this site can at least describe what the regulated version costs, so the reader has something to measure the grey market against. There is no regulated version of Epithalon, so this one cannot. The absence is structural rather than a gap in our research, and it is the single most important thing on the page.

A pharmacy compounding under section 503A of the Federal Food, Drug and Cosmetic Act may work from a bulk drug substance only if one of three things is true: the substance complies with a United States Pharmacopeia or National Formulary monograph, or it is a component of an FDA-approved drug product, or it appears on FDA's 503A bulks list. The agency sets that test out on its bulk drug substances page, content current as of 14 May 2026. Epitalon fails all three. No monograph exists for it. No approved drug product contains it, because none has ever been approved. And it appears on no part of the list.

That last point has a history, and the history is where the misinformation concentrates. Epitalon was nominated for the bulks list, was placed in category 2 under FDA's interim policies while the agency evaluated it, and the nomination was then withdrawn. It appears today on no category list at all. So a page telling you Epitalon is category 2 is repeating something that stopped being true, and a page telling you it was banned has invented a verdict the agency never issued. Withdrawn is the accurate word. For a buyer the practical effect is identical either way: no pharmacy can lawfully compound it, and no prescriber can route around that. Our account of the identical withdrawn nomination sitting behind Selank traces the same sequence on the peptide most often stocked next to this one.

The agency also published its reason, and it is the sentence that should shape how you read every certificate below. From FDA's page on bulk drug substances that may present significant safety risks: "Compounded drugs containing epitalon may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has not identified safety-related information regarding epitalon for the proposed route of administration."

Read that carefully, because it has two halves that point in different directions. Aggregation and peptide-related impurities are manufacturing and handling problems, which means part of what the agency named is exactly the sort of thing a laboratory can measure and report. The rest of it, whether the substance would cause harm in a person, is not something any batch report addresses at all. Both halves survive to the end of this article.

What follows is a framework you can carry to any listing, written as questions about documents rather than as a verdict on one company. Each line has an answer that is either printed on a certificate or is not, which is the useful property: it does not require you to judge tone, web design or how confident the copy sounds. The table sets out what each line proves, what its absence tells you, and how the listing this page links performs against it.

Two of these carry more weight than the rest for anything that would be injected. The endotoxin screen and the microbial sterility screen are the two most commonly missing from certificates in this market, and they are the two that speak most directly to what the agency flagged. A seller publishing purity alone has answered the cheapest question and skipped the expensive ones. Our comparison of how certificates were graded across the Semax market shows how far apart two sellers can sit while both showing you a number beginning with 99.

The sixth line, measured net content, is the one almost nobody looks at, and it is the one that quietly changes what you pay per milligram.

Ascension Peptides publishes one certificate for this compound: batch 15-05260628, tested by Kovera Labs, report KVR-2026-A36FF4, certified 23 May 2026. Open it rather than taking our summary on trust. There is only one document for Epithalon, which is worth noting because the same vendor carries two certificates each for Selank and Semax, and in both of those cases the older one is considerably thinner than the newer.

Purity reports at 99.312 percent against a stated specification of greater than 98 percent, which is the shape you want: a measured result and a pass line to measure it against. Identity is confirmed. The endotoxin safety screen passes against a limit of 0.5 EU/mL or lower. The microbial sterility screen reports no growth. Heavy metals are screened, arsenic, cadmium and mercury among them. Against the checklist above that is a clean sweep of the tests, and it is more than this market typically shows.

Then there is the line that runs the other way. Net content assays at 9.64 mg in a vial labelled 10 mg. The specification is 10 mg plus or minus 10 percent, so 9.64 sits comfortably inside tolerance and the batch passes on that line as well. It is still under the label, by 0.36 mg, which is 3.6 percent of what the front of the vial claims.

That number is worth more than it first appears, and it points in two directions at once. A vendor printing a figure slightly against its own interest is telling you something real about how it handles documents, and it is the mirror image of what the same company's Selank lot did, where the assay came back at 12.29 mg against a 10 mg label and the buyer received extra. Publishing the number in either direction is the behaviour you want to see. But it also means the per-milligram arithmetic quoted in every listing is not the arithmetic you actually receive, and the honest version of the price is slightly higher than the advertised one.

The vial holds 10 mg on the label. List price is $50.00, marked down from $69.99, and the code PEPTIDEDECK takes it to $25.00. On the label figure that is $2.50 per milligram. On the 9.64 mg the certificate actually measured, it is $2.59 per milligram. Both are true, and only one of them ever appears in marketing. Figures checked against the listing on 23 August 2026.

The gap is 3.7 percent: small enough that nobody would notice it, large enough that it should be printed somewhere. It matters most when you are comparing sellers on a per-milligram basis, which is the only sensible way to compare vials of different sizes. Do that across this market and you are almost always comparing one measured content figure against a row of unmeasured label claims, because most sellers never assay the fill at all. A cheaper listing carrying no net content line is not cheaper than this one. It is unmeasured, which is a different thing.

Quantity tiers work separately from the code: buying 3, 5 or 10 vials takes 3 percent, 5 percent or 10 percent off the list price, and free shipping starts at $250. Whether the code and the tiers combine at checkout is not documented anywhere we can point you at, so do not build a purchase around the assumption that they do.

Every criterion above is about manufacturing, and that is the right target. Aggregation and peptide-related impurities are manufacturing problems, and testing is the correct instrument for them. A batch assayed for purity, confirmed for identity, screened for endotoxin and showing no microbial growth has addressed a genuine part of what the agency named, and sellers who skip those tests should not receive the same credit for a listing that looks identical from the outside.

What no certificate produces is human safety data. The agency's second sentence is precisely about that gap: it has not identified safety-related information for the proposed route of administration. A clean result on batch 15-05260628 means that batch was well made. It says nothing whatsoever about what the compound does inside a person, and both of those statements are true at the same time. Any page that shows you only the first one is selling you something.

This matters more for Epithalon than for most peptides on the same shelf, because of who it is sold to and on what basis. The pitch is longevity, and the buyers it reaches are older and more motivated than the average research-peptide customer. The claims that circulate about telomeres and lifespan trace largely to Russian-language work from a single research group, and they are claims made by parties who market the compound rather than findings a Western regulator has reviewed and accepted. Reporting what is claimed, and by whom, is fair. Adopting it is not, and no laboratory report moves that line by a millimetre.

That combination, a strong pitch aimed at motivated buyers with nothing regulated standing behind it, is the exact situation this site exists to describe. Our piece on what a longevity clinic is really selling when it prices NAD+ by the session follows the same audience being sold a different molecule through a channel that at least has a pharmacy behind part of it.

Run the checklist across the market and it removes almost everything. It removes marketplace listings that supply a certificate for a batch other than the one shipped. It removes resellers who buy bulk and repackage into vials, because repackaging severs the link between the document and the container while creating exactly the handling conditions the aggregation concern is about. It removes shops publishing a purity percentage with no specification behind it. And it removes anything arriving with no measured fill weight, which is most of what is on sale.

What survives is a domestic seller shipping a sealed lyophilised vial with a lot-specific certificate you can open before you pay. That is the best available answer to epithalon where to buy, and it is worth being exact about what it is best at. It is not a substitute for a prescription, because no prescription exists to substitute for. It is the only channel where the evidence arrives before the money does.

Which leaves the decision where it belongs, with the reader. The paperwork on this batch is better than the market average and the fill weight is honestly reported, including the part that is not flattering. Neither of those is a finding about what the substance does in a human body, and the agency that would normally produce such a finding has said plainly that it lacks the information to. A buyer who holds both halves at once is making an informed decision. A buyer who has been shown only the first half is being marketed to.